ArticleCurrent medicinal chemistry2026
Exploring MFSD9: From Expression Patterns to Therapeutic Implications in LUAD.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study explores the role of Major Facilitator Superfamily Domain-containing Protein 9 (MFSD9) in lung adenocarcinoma (LUAD) using bioinformatics and experimental validation, aiming to identify its potential as a biomarker and therapeutic target.
methodsComprehensive analysis of MFSD9 expression across cancers, particularly LUAD, was carried out using The Cancer Genome Atlas (TCGA) dataset. Correlations between MFSD9 expression and clinical outcomes, immune infiltration, immune checkpoint genes, tumor mutational burden (TMB), microsatellite instability (MSI), mRNA expression-stemness index (mRNAsi), and drug sensitivity were examined. Validation was performed using the Human Protein Atlas (HPA), Gene Expression Omnibus (GEO) databases, and qRT-PCR in LUAD cell lines.
resultsMFSD9 was significantly overexpressed in LUAD, correlating with reduced overall survival (OS) and progression-free survival (PFS) (p = 0.044 and p = 0.026, respectively). It was found to be an independent prognosis factor (p = 0.046). MFSD9 expression was associated with immune cell infiltration, immune checkpoint genes, TMB, MSI, and mRNAsi, and inversely correlated with sensitivity to certain drugs, including zygosporin A and lovastatin. DISCUSSION: MFSD9 shows promise as a prognostic biomarker and therapeutic target in LUAD. Its role in immune modulation and tumor progression highlights its potential for immunotherapy. However, further experimental validation is needed to address study limitations.
conclusionMFSD9 is a potential biomarker and therapeutic target in LUAD, with significant implications for prognosis and treatment response. Future studies should focus on functional validation and clinical application.
Indexed as
Identifiers
40605165What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.